Article Text

Download PDFPDF

Authors’ response to Murray et al
  1. Amelia O Clive1,2,
  2. Brennan C Kahan3,
  3. Nick A Maskell1,2
  1. 1 Academic Respiratory Unit, University of Bristol, Bristol, UK
  2. 2 North Bristol Lung Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK
  3. 3 Pragmatic Clinical Trials Unit, Queen Mary University of London, London, UK
  1. Correspondence to Dr Nick A Maskell, Academic Respiratory Unit, Second Floor, Learning and Research Building, Southmead Hospital, University of Bristol, Bristol BS10 5NB, UK; nick.maskell{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Murray et al for their interest and complementary comments regarding the LENT score (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group (ECOG) performance score (PS), neutrophil-to-lymphocyte ratio and tumour type).1 We are pleased they felt it would be a beneficial addition to multidisciplinary team discussions.

We agree with their observation that the survival differences between cell types may reflect different stages of disease at presentation with malignant pleural effusion (MPE) or the availability of subsequent effective therapies for some of the underlying tumour types. However, when designing the LENT score we chose to use the cell types themselves rather than …

View Full Text

Linked Articles